WEBULL
WebtradeDownload

Indoco Remedies Shares Slid Even Though It Turned A Profit

Simply Wall St · 3d ago

Q1 2027 put Indoco Remedies back in the headlines, with revenue of ₹4,675.0 million and net income of ₹649.9 million reported on 21 August 2026 after a loss a year earlier. For Indoco Remedies shareholders, the loss over the past year was 20.6%, including dividends. If you had put money in a year ago expecting regulatory fixes and aging trends to help, how much confidence would you still have in those original earnings assumptions?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

If the move has made Indoco Remedies harder to judge, start where the gap is still open and scan 195 high quality undervalued stocks.

The Two Indoco Remedies Stories Investors Had To Weigh

The shares cost ₹281 at the start of the period, and anyone looking at Indoco Remedies then had two very different stories to weigh.

The bullish narrative put fair value at ₹325, assuming fresh regulatory approvals and digital upgrades would support revenue growth in higher value sterile markets and help lift margins well above earlier levels.

The bearish view anchored fair value at ₹260 and focused on risks, including sustained pressure from compliance costs, input price inflation and a modest R&D effort that could limit complex drug opportunities.

NSEI:INDOCO 1-Year Stock Price Chart
NSEI:INDOCO 1-Year Stock Price Chart

What The Indoco Remedies Results Actually Tested

Q1 2027 gave Indoco Remedies a clean test of those 2025 stories. Revenue was ₹4,675.0m against ₹4,378.9m a year earlier, while a prior loss of ₹357.9m turned into net income of ₹649.9m and net margin moved from -8.2% to 13.9%. That swing supported the more optimistic view on profitability, even if it was only one quarter.

The main takeaway is straightforward: when an investment case focuses on margin repair rather than just sales growth, it is important to track net income and net margin in the results, not just the top line.

What Indoco Remedies' Lower Price Now Asks You To Believe

Indoco Remedies shares are ₹220 today, down from ₹281 over the past year, and the selected Narrative’s Fair Value sits above that level based on its own framework.

The Narrative focuses on efficiency initiatives, regulated market exposure and deleveraging. A buyer now would need to believe margin-focused manufacturing changes can be sustained while regulatory and input cost pressures stay manageable.

"Key Takeaways For Indoco Remedies, analysts expect operational efficiency measures, a higher mix of regulated markets and APIs, and tighter capital spending to support a more resilient earnings profile and keep the business on a steady footing. The main thing that has to go right is that Indoco Remedies continues to execute on margin-focused manufacturing changes, brand-led domestic growth, and balance sheet repair while managing input cost pressure and regulatory constraints at key facilities."

The price and this Narrative do not agree. → Uncover what this Narrative says Indoco Remedies is actually worth

Go Straight To The Source

This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.

  • Company 1 - 50% below our estimate - uses an AI focused security platform and subscriptions to lift recurring service revenue.
  • Company 2 - 22% below our estimate - ties cloud, productivity software and AI tools together to deepen long term customer lock in.
  • Company 3 - 17% below our estimate - targets large network operators whose rising AI bandwidth needs drive multi year optical contracts.

Three companies from the same screener. Open every one of the 207 solid balance sheet companies →